Calvo-Torres L F, Bernal-Cobo R, Trujillo-Quintero P M, Gaviria-Mendoza A, Machado-Alba J E
Universidad Tecnologica de Pereira-Audifarma S.A, Pereira, Colombia.
Universidad Nacional de Colombia, Bogota, Colombia.
Rev Neurol. 2019 May 16;68(10):409-416. doi: 10.33588/rn.6810.2018361.
The benefits of pharmacological therapy with anti-dementia drugs are not yet fully demonstrated and there is even a lack of publications describing their use profile. The present work sought to determine the prescription patterns of anti-dementia drugs in a Colombian population.
Descriptive cross-sectional study. Through a systematized database of 3.5 million affiliates to the Colombian health system, patients with uninterrupted dispensing of anti-dementia drugs between August-October/2016 were selected. Sociodemographic, pharmacological and comedication variables were analyzed. The costs of the therapies were estimated from the reference price of the medicines.
We identified 8372 patients with a mean age of 79.5 ± 8.7 years and 65.3% (n = 5471) were women. The most widely used medication was rivastigmine (69.6%), mainly in transdermal presentation, followed by memantine (31.4%). In general, the average dose administered per day was lower than the defined daily dose. Only 568 patients (6.7%) used combination therapy. 84.3% of patients (n = 7061) used some additional medication and 54.2% (n = 4535) had another neurologic medication. The cost per 1000 inhabitants/day of rivastigmine was 3.47 USD and for memantine 0.30 USD.
Patients with anti-dementia drugs are using them at doses lower than those defined and they present an important frequency of comorbidities and comedications.
抗痴呆药物的药物治疗益处尚未得到充分证明，甚至缺乏描述其使用情况的出版物。本研究旨在确定哥伦比亚人群中抗痴呆药物的处方模式。
描述性横断面研究。通过哥伦比亚卫生系统350万参保人的系统化数据库，选取2016年8月至10月期间持续配用抗痴呆药物的患者。分析社会人口统计学、药理学和合并用药变量。根据药品参考价格估算治疗费用。
我们确定了8372例患者，平均年龄为79.5±8.7岁，65.3%（n = 5471）为女性。使用最广泛的药物是卡巴拉汀（69.6%），主要为透皮剂型，其次是美金刚（31.4%）。总体而言，每日平均给药剂量低于规定日剂量。只有568例患者（6.7%）使用联合治疗。84.3%的患者（n = 7061）使用了一些其他药物，54.2%（n = 4535）有另一种神经科药物。每1000居民/天卡巴拉汀的费用为3.47美元，美金刚为0.30美元。
使用抗痴呆药物的患者用药剂量低于规定剂量，且合并症和合并用药的发生率较高。
